EP. 7 IO Monotherapy Versus Combination Dual IO Therapy for the First-Line Treatment of Metastatic Melanoma
EP. 9 Managing Adverse Events in Patients With Metastatic Melanoma Receiving First-Line Systemic Therapy
EP. 11 Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma with a BRAF Mutation
EP. 12 Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib in Metastatic Melanoma: Data From the DREAMseq Trial
EP. 13 Second-Line Treatment Options for Patients With Metastatic or Unresectable Melanoma After Disease Progression
October 24th, 2026Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium IRecap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.Read more
October 23rd, 2026Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma RecurrenceAdding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.Read more